Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 4454 entries
Sorted by: Best Match Show Resources per page
Rituximab-Induced Acute ST Elevation Myocardial Infarction.

The Ochsner journal

Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E.
PMID: 26130984
Ochsner J. 2015;15(2):187-90.

BACKGROUND: Rituximab has rarely been associated with acute coronary syndrome (ACS). We report the case of a patient in whom rituximab, a monoclonal antibody used to treat lymphomas of B-cell origin, induced ST elevation myocardial infarction.CASE REPORT: A 46-year-old...

Cite
Keswani AN, Williams C, Fuloria J, et al. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90
Keswani, A. N., Williams, C., Fuloria, J., Polin, N. M., & Jahangir, E. (2015). Rituximab-Induced Acute ST Elevation Myocardial Infarction. The Ochsner journal, 15(2), 187-90.
Keswani, Amit N, et al. "Rituximab-Induced Acute ST Elevation Myocardial Infarction." The Ochsner journal vol. 15,2 (2015): 187-90.
Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187-90. PMID: 26130984; PMCID: PMC4482563.
Copy Download .nbib Format: NLM
Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Experimental hematology & oncology

Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G.
PMID: 25671135
Exp Hematol Oncol. 2015 Jan 14;4(1):3. doi: 10.1186/2162-3619-4-3. eCollection 2015.

BACKGROUND: Castleman-Kojima disease (TAFRO Syndrome) is characterized by Thrombocytopenia, Anasarca, myeloFibrosis, Renal dysfunction, Organomegaly, multiple lymphadenopathy and histopathology pattern of atypical Castleman's disease (CD). Only few cases of this recently identified unique variant of Multicentric CD (MCD) are described...

Cite
Tedesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol. 2015;4(1):3doi: 10.1186/2162-3619-4-3.
Tedesco, S., Postacchini, L., Manfredi, L., Goteri, G., Luchetti, M. M., Festa, A., Gabrielli, A., & Pomponio, G. (2015). Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Experimental hematology & oncology, 4(1), 3. https://doi.org/10.1186/2162-3619-4-3
Tedesco, Silvia, et al. "Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report." Experimental hematology & oncology vol. 4,1 (2015): 3. doi: https://doi.org/10.1186/2162-3619-4-3
Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, Gabrielli A, Pomponio G. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol. 2015 Jan 14;4(1):3. doi: 10.1186/2162-3619-4-3. eCollection 2015. PMID: 25671135; PMCID: PMC4322808.
Copy Download .nbib Format: NLM
Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis.

Lower urinary tract symptoms

Nasrin S, Masuda E, Kugaya H, Osano A, Ito Y, Yamada S.
PMID: 26663502
Low Urin Tract Symptoms. 2014 Jan;6(1):57-63. doi: 10.1111/luts.12015. Epub 2013 Mar 15.

OBJECTIVES: To clarify the effect of saw palmetto extract (SPE), a phytotherapeutic agent, on urodynamic parameters, bladder muscarinic and purinergic receptors, and urinary cytokines in rats with cystitis induced by cyclophosphamide (CYP).METHODS: Saw palmetto extract (60 mg/kg per day)...

Cite
Nasrin S, Masuda E, Kugaya H, et al. Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis. Low Urin Tract Symptoms. 2013;6(1):57-63doi: 10.1111/luts.12015.
Nasrin, S., Masuda, E., Kugaya, H., Osano, A., Ito, Y., & Yamada, S. (2014). Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis. Lower urinary tract symptoms, 6(1), 57-63. https://doi.org/10.1111/luts.12015
Nasrin, Sweety, et al. "Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis." Lower urinary tract symptoms vol. 6,1 (2014): 57-63. doi: https://doi.org/10.1111/luts.12015
Nasrin S, Masuda E, Kugaya H, Osano A, Ito Y, Yamada S. Effects of Saw Palmetto Extract on Urodynamic Parameters, Bladder Muscarinic and Purinergic Receptors and Urinary Cytokines in Rats with Cyclophosphamide-Induced Cystitis. Low Urin Tract Symptoms. 2014 Jan;6(1):57-63. doi: 10.1111/luts.12015. Epub 2013 Mar 15. PMID: 26663502.
Copy Download .nbib Format: NLM
Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report.

Oncology letters

Song K, Li M.
PMID: 26137030
Oncol Lett. 2015 May;9(5):2153-2156. doi: 10.3892/ol.2015.3010. Epub 2015 Mar 03.

A 39-year-old female presented to The First Affiliated Hospital of Jishou University (Jishou, Hunan) with a fever of unknown origin and progressive abdominal distension. Physical examination revealed generalized lymphadenopathy, multiple non-tender cutaneous nodules, hepatomegaly, splenomegaly and abdominal edema. An...

Cite
Song K, Li M. Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. Oncol Lett. 2015;9(5):2153-2156doi: 10.3892/ol.2015.3010.
Song, K., & Li, M. (2015). Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. Oncology letters, 9(5), 2153-2156. https://doi.org/10.3892/ol.2015.3010
Song, Kui, and Li, Min. "Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report." Oncology letters vol. 9,5 (2015): 2153-2156. doi: https://doi.org/10.3892/ol.2015.3010
Song K, Li M. Budd-Chiari syndrome, a rare complication of multicentric Castleman disease: A case report. Oncol Lett. 2015 May;9(5):2153-2156. doi: 10.3892/ol.2015.3010. Epub 2015 Mar 03. PMID: 26137030; PMCID: PMC4467279.
Copy Download .nbib Format: NLM
Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report.

Journal of clinical and diagnostic research : JCDR

Tomioka H, Kaneoya A, Mochizuki Y, Harada H.
PMID: 26266230
J Clin Diagn Res. 2015 Jun;9(6):ZD25-7. doi: 10.7860/JCDR/2015/12121.6107. Epub 2015 Jun 01.

Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder that is characterized by progressive cerebellar ataxia, telangiectasia, immunodeficiency, and a predisposition to leukemia/lymphoma. Here we report a rare case of lymphoma of the tongue accompanied by AT. Tumour extirpation was...

Cite
Tomioka H, Kaneoya A, Mochizuki Y, et al. Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. J Clin Diagn Res. 2015;9(6):ZD25-7doi: 10.7860/JCDR/2015/12121.6107.
Tomioka, H., Kaneoya, A., Mochizuki, Y., & Harada, H. (2015). Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. Journal of clinical and diagnostic research : JCDR, 9(6), ZD25-7. https://doi.org/10.7860/JCDR/2015/12121.6107
Tomioka, Hirofumi, et al. "Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report." Journal of clinical and diagnostic research : JCDR vol. 9,6 (2015): ZD25-7. doi: https://doi.org/10.7860/JCDR/2015/12121.6107
Tomioka H, Kaneoya A, Mochizuki Y, Harada H. Primary Diffuse Large B-cell Lymphoma Arising in the Tongue Accompanied by Ataxia-telangiectasia: A Case Report. J Clin Diagn Res. 2015 Jun;9(6):ZD25-7. doi: 10.7860/JCDR/2015/12121.6107. Epub 2015 Jun 01. PMID: 26266230; PMCID: PMC4525621.
Copy Download .nbib Format: NLM
A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase.

Molecular therapy. Nucleic acids

Podetz-Pedersen KM, Olson ER, Somia NV, Russell SJ, McIvor RS.
PMID: 26784638
Mol Ther Nucleic Acids. 2016 Jan 19;5:e279. doi: 10.1038/mtna.2015.54.

The Sleeping Beauty (SB) transposon system has been shown to enable long-term gene expression by integrating new sequences into host cell chromosomes. We found that the recently reported SB100x hyperactive transposase conferred a surprisingly high level of long-term expression...

Cite
Podetz-Pedersen KM, Olson ER, Somia NV, et al. A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase. Mol Ther Nucleic Acids. 2016;5:e279doi: 10.1038/mtna.2015.54.
Podetz-Pedersen, K. M., Olson, E. R., Somia, N. V., Russell, S. J., & McIvor, R. S. (2016). A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase. Molecular therapy. Nucleic acids, 5e279. https://doi.org/10.1038/mtna.2015.54
Podetz-Pedersen, Kelly M, et al. "A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase." Molecular therapy. Nucleic acids vol. 5 (2016): e279. doi: https://doi.org/10.1038/mtna.2015.54
Podetz-Pedersen KM, Olson ER, Somia NV, Russell SJ, McIvor RS. A Broad Range of Dose Optima Achieve High-level, Long-term Gene Expression After Hydrodynamic Delivery of Sleeping Beauty Transposons Using Hyperactive SB100x Transposase. Mol Ther Nucleic Acids. 2016 Jan 19;5:e279. doi: 10.1038/mtna.2015.54. PMID: 26784638; PMCID: PMC5012552.
Copy Download .nbib Format: NLM
Minimal-change disease in adolescents and adults: epidemiology and therapeutic response.

Clinical kidney journal

Keskar V, Jamale TE, Kulkarni MJ, Kiggal Jagadish P, Fernandes G, Hase N.
PMID: 26064510
Clin Kidney J. 2013 Oct;6(5):469-72. doi: 10.1093/ckj/sft063.

BACKGROUND: Epidemiology of minimal-change disease (MCD) in adults differs from that in children and is not studied well in Indian population.METHODS: We retrospectively studied the records of 61 adult patients with MCD to assess clinical, laboratory and histopathological features,...

Cite
Keskar V, Jamale TE, Kulkarni MJ, et al. Minimal-change disease in adolescents and adults: epidemiology and therapeutic response. Clin Kidney J. 2013;6(5):469-72doi: 10.1093/ckj/sft063.
Keskar, V., Jamale, T. E., Kulkarni, M. J., Kiggal Jagadish, P., Fernandes, G., & Hase, N. (2013). Minimal-change disease in adolescents and adults: epidemiology and therapeutic response. Clinical kidney journal, 6(5), 469-72. https://doi.org/10.1093/ckj/sft063
Keskar, Vaibhav, et al. "Minimal-change disease in adolescents and adults: epidemiology and therapeutic response." Clinical kidney journal vol. 6,5 (2013): 469-72. doi: https://doi.org/10.1093/ckj/sft063
Keskar V, Jamale TE, Kulkarni MJ, Kiggal Jagadish P, Fernandes G, Hase N. Minimal-change disease in adolescents and adults: epidemiology and therapeutic response. Clin Kidney J. 2013 Oct;6(5):469-72. doi: 10.1093/ckj/sft063. PMID: 26064510; PMCID: PMC4438390.
Copy Download .nbib Format: NLM
Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience.

International journal of clinical and experimental medicine

Berber I, Erkurt MA, Nizam I, Koroglu M, Kaya E, Kuku I, Bag HG.
PMID: 26629149
Int J Clin Exp Med. 2015 Sep 15;8(9):16308-14. eCollection 2015.

High-dose chemotherapy (HDC) applied together with autologous stem cell transplantation (ASCT) is a commonly used treatment modality in patients with malignant lymphoma. At present, there is a limited number of studies which compare toxicity and efficacy of various high-dose...

Cite
Berber I, Erkurt MA, Nizam I, et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015;8(9):16308-14
Berber, I., Erkurt, M. A., Nizam, I., Koroglu, M., Kaya, E., Kuku, I., & Bag, H. G. (2015). Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. International journal of clinical and experimental medicine, 8(9), 16308-14.
Berber, Ilhami, et al. "Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience." International journal of clinical and experimental medicine vol. 8,9 (2015): 16308-14.
Berber I, Erkurt MA, Nizam I, Koroglu M, Kaya E, Kuku I, Bag HG. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015 Sep 15;8(9):16308-14. eCollection 2015. PMID: 26629149; PMCID: PMC4659037.
Copy Download .nbib Format: NLM
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes.

Diabetes, metabolic syndrome and obesity : targets and therapy

Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A.
PMID: 25759591
Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. doi: 10.2147/DMSO.S76342. eCollection 2015.

PURPOSE: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2...

Cite
Powell DR, Doree D, Jeter-Jones S, et al. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes Metab Syndr Obes. 2015;8:121-7doi: 10.2147/DMSO.S76342.
Powell, D. R., Doree, D., Jeter-Jones, S., Ding, Z. M., Zambrowicz, B., & Sands, A. (2015). Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy, 8121-7. https://doi.org/10.2147/DMSO.S76342
Powell, David R, et al. "Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 8 (2015): 121-7. doi: https://doi.org/10.2147/DMSO.S76342
Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A. Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes. Diabetes Metab Syndr Obes. 2015 Feb 26;8:121-7. doi: 10.2147/DMSO.S76342. eCollection 2015. PMID: 25759591; PMCID: PMC4346285.
Copy Download .nbib Format: NLM
Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma.

Biomolecules & therapeutics

Ou Y, Li Q, Wang J, Li K, Zhou S.
PMID: 25143814
Biomol Ther (Seoul). 2014 Jul;22(4):341-6. doi: 10.4062/biomolther.2013.106.

Paeonol is a major phenolic micromolecular component of Moutan cortex Radicis, a traditional Chinese Medicine. It has shown antitumor effects in previous studies; however, the underlying mechanisms remain unknown. This study investigated the mechanism by giving treatments of placebo,...

Cite
Ou Y, Li Q, Wang J, et al. Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma. Biomol Ther (Seoul). 2014;22(4):341-6doi: 10.4062/biomolther.2013.106.
Ou, Y., Li, Q., Wang, J., Li, K., & Zhou, S. (2014). Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma. Biomolecules & therapeutics, 22(4), 341-6. https://doi.org/10.4062/biomolther.2013.106
Ou, Yetao, et al. "Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma." Biomolecules & therapeutics vol. 22,4 (2014): 341-6. doi: https://doi.org/10.4062/biomolther.2013.106
Ou Y, Li Q, Wang J, Li K, Zhou S. Antitumor and Apoptosis Induction Effects of Paeonol on Mice Bearing EMT6 Breast Carcinoma. Biomol Ther (Seoul). 2014 Jul;22(4):341-6. doi: 10.4062/biomolther.2013.106. PMID: 25143814; PMCID: PMC4131527.
Copy Download .nbib Format: NLM
Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model.

Haemophilia : the official journal of the World Federation of Hemophilia

Nilsson IM, Berntorp E, Rickard KA.
PMID: 27214223
Haemophilia. 1995 Jan;1(1):59-66. doi: 10.1111/j.1365-2516.1995.tb00041.x.

Development of inhibitors to factor IX (F IX) is a serious complication of the treatment of patients with severe haemophilia B. Three Australian haemophilia B patients, a 22-year-old man and two 5-year-old identical twins, with high-responding inhibitors and resistant...

Cite
Nilsson IM, Berntorp E, Rickard KA. Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model. Haemophilia. 1995;1(1):59-66doi: 10.1111/j.1365-2516.1995.tb00041.x.
Nilsson, I. M., Berntorp, E., & Rickard, K. A. (1995). Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model. Haemophilia : the official journal of the World Federation of Hemophilia, 1(1), 59-66. https://doi.org/10.1111/j.1365-2516.1995.tb00041.x
Nilsson, I M, et al. "Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model." Haemophilia : the official journal of the World Federation of Hemophilia vol. 1,1 (1995): 59-66. doi: https://doi.org/10.1111/j.1365-2516.1995.tb00041.x
Nilsson IM, Berntorp E, Rickard KA. Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model. Haemophilia. 1995 Jan;1(1):59-66. doi: 10.1111/j.1365-2516.1995.tb00041.x. PMID: 27214223.
Copy Download .nbib Format: NLM
Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia

Maliekel K, Rana N, Green D.
PMID: 27214621
Haemophilia. 1997 Jan;3(1):54-8. doi: 10.1046/j.1365-2516.1997.00075.x.

Bleeding in nonhaemophilic patients with high-titre factor VIII autoantibodies is often severe, life-threatening and refractory to treatment with factor VIII concentrates. In this report, we describe an elderly woman who required surgical excision of a large haemophilic pseudotumour adjacent...

Cite
Maliekel K, Rana N, Green D. Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia. Haemophilia. 1997;3(1):54-8doi: 10.1046/j.1365-2516.1997.00075.x.
Maliekel, K., Rana, N., & Green, D. (1997). Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia. Haemophilia : the official journal of the World Federation of Hemophilia, 3(1), 54-8. https://doi.org/10.1046/j.1365-2516.1997.00075.x
Maliekel, K, et al. "Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia." Haemophilia : the official journal of the World Federation of Hemophilia vol. 3,1 (1997): 54-8. doi: https://doi.org/10.1046/j.1365-2516.1997.00075.x
Maliekel K, Rana N, Green D. Recombinant factor VIIa in the management of a pseudotumour in acquired haemophilia. Haemophilia. 1997 Jan;3(1):54-8. doi: 10.1046/j.1365-2516.1997.00075.x. PMID: 27214621.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 4454 entries